<DOC>
	<DOCNO>NCT01603875</DOCNO>
	<brief_summary>Pre exposure rabies vaccination new Chromatographically Purified Vero-cell Rabies Vaccine ( SPEEDA ) effective Purified Vero-cell Rabies vaccine . After pre exposure rabies vaccination new Chromatographically Purified Vero-cell Rabies Vaccine ( SPEEDA ) , Rabies neutralize antibody patient day 42 0.5 IU/ml . And Simulated post-exposure rabies booster vaccination new Chromatographically Purified Vero-cell Rabies Vaccine ( SPEEDA ) effective Purified Vero-cell Rabies vaccine . After simulated post-exposure rabies booster vaccination new Chromatographically Purified Vero-cell Rabies Vaccine ( SPEEDA ) , Rabies neutralize antibody patient day 14 booster 0.5 IU/ml .</brief_summary>
	<brief_title>Immune Response Adults PrEP Simulated Booster PEP With New CPRV</brief_title>
	<detailed_description>Pre-exposure vaccination do accord standard protocol . Participants inject one dose day 0 , 7 28 . Blood sample take day 0 , 28 42 first vaccination dose . 360 day later , participant receive simulate post-exposure rabies booster vaccination one dose day 0 3 . Blood sample take day 0 ( 360 day ) 14 ( 374 day ) booster vaccination . Rabies neutralize antibody level measure Rapid Fluorescent Focus Inhibition Test ( RFFIT ) . And level 0.5 IU/ml consider acceptable protective level . For statistical analysis , percentage subject achieve seroconversion ( define RNab ≥ 0.5 IU/ mL ) determine sample time . The average titer use study Geometric mean titer ( GMT ) . 95 percent confidence interval ( 95 % CI ) GMT calculate study group individual measurement serum rabies antibody level sample time . One-way ANOVA would use calculated significance difference GMT three group , SPEEDA® intradermal injection , SPEEDA® intramuscular injection PVRV intramuscular injection . The primary criterion comparison rabies antibody value day 42 ( 2 week third vaccine dose pre-exposure vaccination ) day 374 ( 2 week first vaccine dose booster vaccination ) . Results deem statistically significant p &lt; 0.05 . Safety data ( immediate , local systemic reaction ) summarize number percentage .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy Can visit accord protocol Fever Acute illness History rabies vaccination Allergic vaccine ' component Immunosuppressive condition HIV infection , transplantation , chronic renal failure , receive steroid immunosuppressive drug antimalarial drug within previous two month blood product within previous three month Female participant must pregnant All female participant must urine pregnancy test negative prior participate study</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>CPRV</keyword>
	<keyword>SPEEDA</keyword>
	<keyword>intradermal</keyword>
	<keyword>pre-exposure</keyword>
	<keyword>booster</keyword>
</DOC>